Endocarditis caused by methicillin-resistant Staphylococcus aureus: Treatment failure with linezolid

Clinical Infectious Diseases

Volumn 35, Issue 8, 2002, Pages 1018-1020

  Ruiz, Maria E ^a   Guerrero, Isabel C ^b   Tuazon, Carmelita U ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b Community Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; GENTAMICIN; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

AGED; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; ENDOCARDITIS; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ACETAMIDES; AGED; ANTI-BACTERIAL AGENTS; ENDOCARDITIS, BACTERIAL; HUMANS; METHICILLIN RESISTANCE; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE;

EID: 0037108388     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/342698     Document Type: Article

References (10)

1. Babcock HM, Ritchie DJ, Christiansen E, et al. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis 2001; 32:1373-5.
2. McNeil SA, Clark NM, Chandrasekar PH, et al. Successful treatment of vancomycin-resistant Enterococcusfaecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin). Clin Infect Dis 2000; 30:403-4.
3. Meltzer M, Goldsmith D, Gransden W. Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias. Clin Infect Dis 2000; 31: 208-9.
4. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcusaureus endocarditis. Ann Intern Med 1991; 115:674-80.
5. Mallory MA, Nettles RE, Alspaugh A, et al. Community-acquired prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1997; 24:272-3.
6. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7:327-32.
7. Leach TS, Kaja RW, Eckert SM, et al. Linezolid versus vancomycin for the treatment of MRSA infections: results of a randomized phase III trial [abstract 95-079]. In: Program and abstracts of the 9th International Congress on Infectious Diseases. Boston: International Society for Infectious Dieases; 2000:224.
8. Oramas-Shirey MP, Buchanan LV, Dileto-Fang CL, et al. Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J Antimicrob Chemother 2001; 47:349-52.
9. Dailey CF, Dileto-Fang CL, Buchanan LV, et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45:2304-8.
10. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207-8.